Neurocrine Biosciences (NBIX) was Initiated by Oppenheimer to “Perform”. Oppenheimer advised their investors in a research report released on Nov 22, 2016.
Many Wall Street Analysts have commented on Neurocrine Biosciences. Deutsche Bank Initiated Neurocrine Biosciences on Nov 3, 2016 to “Buy”, Price Target of the shares are set at $65.Needham Initiated Neurocrine Biosciences on Oct 18, 2016 to “Buy”, Price Target of the shares are set at $62.Leerink Partners Resumed Neurocrine Biosciences on Oct 4, 2016 to “Outperform”, Price Target of the shares are set at $70.
On the company’s financial health, Neurocrine Biosciences reported $-0.43 EPS for the quarter, beating the analyst consensus estimate by $ 0.14 according to the earnings call on Nov 2, 2016. Analyst had a consensus of $-0.57.During the same quarter in the previous year, the company posted $-0.40 EPS.
Neurocrine Biosciences closed down -1.26 points or -2.41% at $51.01 with 6,48,876 shares getting traded on Monday. Post opening the session at $52.48, the shares hit an intraday low of $50.54 and an intraday high of $52.59 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Nov 16, 2016, Christopher Flint Obrien (Chief Medical Officer) sold 25,000 shares at $52.84 per share price. According to the SEC, on Sep 2, 2016, Malcolm Lloyd-smith (Chief Regulatory Officer) sold 9,000 shares at $50.00 per share price. On Aug 9, 2016, Corinne H Nevinny (director) sold 5,000 shares at $48.54 per share price, according to the Form-4 filing with the securities and exchange commission.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.